Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Significant Decline in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 1,850,000 shares, a decline of 6.6% from the May 31st total of 1,980,000 shares. Currently, 7.7% of the shares of the company are short sold. Based on an average trading volume of 233,700 shares, the short-interest ratio is presently 7.9 days.

Bolt Biotherapeutics Stock Performance

NASDAQ BOLT opened at $0.74 on Thursday. The company has a quick ratio of 5.68, a current ratio of 5.68 and a debt-to-equity ratio of 0.16. Bolt Biotherapeutics has a twelve month low of $0.72 and a twelve month high of $1.56. The business has a 50-day moving average price of $0.87 and a 200-day moving average price of $1.06. The firm has a market cap of $28.03 million, a price-to-earnings ratio of -0.44 and a beta of 0.94.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.23. Bolt Biotherapeutics had a negative return on equity of 51.74% and a negative net margin of 556.59%. The company had revenue of $5.27 million for the quarter, compared to analysts’ expectations of $2.63 million. As a group, equities research analysts predict that Bolt Biotherapeutics will post -1.4 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on BOLT shares. Leerink Partnrs cut Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 14th. HC Wainwright reaffirmed a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, May 15th. Stifel Nicolaus reissued a “hold” rating and issued a $1.50 target price (down from $6.00) on shares of Bolt Biotherapeutics in a report on Wednesday, May 15th. Guggenheim reaffirmed a “neutral” rating on shares of Bolt Biotherapeutics in a report on Wednesday, May 15th. Finally, SVB Leerink reiterated a “market perform” rating and issued a $1.00 price target (down from $3.00) on shares of Bolt Biotherapeutics in a research report on Wednesday, May 15th. Five analysts have rated the stock with a hold rating, According to MarketBeat.com, Bolt Biotherapeutics has a consensus rating of “Hold” and an average price target of $3.50.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.